Cargando…
Clinical Experience with Ropeginterferon Alfa-2b in the Off-Label Use for the Treatment of COVID-19 Patients in Taiwan
INTRODUCTION: This study, for the first time to our knowledge, evaluated the efficacy of ropeginterferon alfa-2b, a long-acting pegylated interferon (IFN)-alfa, in the treatment of COVID-19. METHODS: We retrospectively evaluated ropeginterferon alfa-2b administered subcutaneously at a single dose of...
Autores principales: | Chen, Kuan-Yuan, Lee, Kang-Yun, Qin, Albert, Luo, Ching-Shan, Yeh, Yun-Kai, Zheng, Jing-Quan, Chen, Ching-Mei, Tsai, Chan-Yen, Lin, Sheena, Liao, Jason, Huang, Yi-Wen, Feng, Po-Hao |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8672342/ https://www.ncbi.nlm.nih.gov/pubmed/34910280 http://dx.doi.org/10.1007/s12325-021-01998-y |
Ejemplares similares
-
Ropeginterferon alfa‐2b in patients with genotype 1 chronic hepatitis C: Pharmacokinetics, safety, and preliminary efficacy
por: Lin, Hsien‐Hong, et al.
Publicado: (2021) -
Ropeginterferon alfa-2b every 2 weeks as a novel pegylated interferon for patients with chronic hepatitis B
por: Huang, Yi-Wen, et al.
Publicado: (2020) -
Ropeginterferon Alfa-2b: Efficacy and Safety in Different Age Groups
por: Gisslinger, Heinz, et al.
Publicado: (2020) -
Cost–effectiveness of ropeginterferon alfa-2b-njft for the treatment of polycythemia vera
por: Gerds, Aaron T, et al.
Publicado: (2023) -
Long-term outcomes of polycythemia vera patients treated with ropeginterferon Alfa-2b
por: Kiladjian, Jean-Jacques, et al.
Publicado: (2022)